Medtronic plc (NYSE: MDT), a leader in healthcare technology, presented compelling new data at the American Diabetes Association’s (ADA) 84th Scientific Sessions, highlighting the MiniMed 780G system’s efficacy in managing hyperglycemia and reducing nighttime burden for individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). This data adds to the growing body of evidence that the MiniMed 780G system addresses the unique challenges of diabetes management, including meal-time management and carb counting.

Hyperglycemia remains a significant challenge for many living with diabetes, with only 26% of U.S. patients achieving HbA1c levels of <7.0%. The MiniMed 780G system has shown to effectively manage this condition, particularly the dawn phenomenon—a common early morning glucose increase. A new retrospective analysis of 6,026 patients demonstrated that upgrading from the MiniMed 770G to the 780G system significantly reduced the incidence of dawn phenomenon and improved Time in Range (TIR) from 87.7% to 91.4% between midnight and 6 a.m.

The MiniMed 780G system also focuses on reducing the nighttime burden, a major concern for those with type 1 diabetes. Data from another retrospective analysis of 8,019 patients showed that the system minimized sleep disruptions and improved overnight Time in Range, thanks to its advanced algorithm that automatically adjusts insulin every five minutes. This resulted in a decrease in nighttime alerts by up to 55% for users with optimized settings, and an increase in uninterrupted sleep by up to 36 minutes per night.

Medtronic continues to innovate with the development of the next iteration of the MiniMed 780G system, intended to pair with the Simplera Sync sensor, a new disposable CGM requiring no overtape. Preliminary results from a 24-site study showed improvements across all clinical outcomes, including TIR, Time in Tight Range (TITR), and Time Above Range (TAR). The system, along with the Simplera Sync sensor, is set to launch in parts of Europe by late July, offering a more streamlined and effective diabetes management experience.

Dr. Gregory Forlenza, a pediatric endocrinologist at the Barbara Davis Center, praised the next iteration of the MiniMed system, noting, “The overall experience for people living with type 1 diabetes could be enhanced and may prove to be a compelling option for diabetes management.”

  ADA scientific sessions, advanced diabetes care, Diabetes management, hyperglycemia treatment, Medtronic, Medtronic MiniMed 780G